sonar LMArena Search Arena 24K
give me the latest updates for bms
- User
give me the latest updates for bms
- Assistant
Here are the latest updates for Bristol Myers Squibb (BMS):
-
Cost-Cutting and Strategic Reorganization:
- BMS has announced an additional 1.5 billion by the end of 2025. This move is part of a broader effort to enhance operational efficiency and prepare for the loss of exclusivity for key drugs like Eliquis and Opdivo around 2028[1].
- The company is focusing on becoming a "leaner, more efficient company" while investing in growth brands and promising scientific areas[1].
-
Acquisitions and Pipeline Development:
- BMS acquired Karuna Therapeutics at the end of 2023 for $14 billion, gaining access to Cobenfy, a treatment for schizophrenia. The company plans to conduct three Phase III trials for Cobenfy[1].
- BMS is actively seeking deals or partnerships to strengthen its pipeline, particularly in core therapeutic areas where the science aligns with their strategic goals[1].
-
Regulatory Approvals:
- BMS received approval from the European Commission to expand the use of its CAR-T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy[3].
-
Financial Performance:
- In the fourth quarter of 2024, BMS reported 45.5 billion[1].
-
Other Initiatives:
- BMS has been recognized with the prestigious Prix Galien Award for its innovative contributions to healthcare[4].
- The company is also involved in community initiatives, such as supporting patients with conditions like Hypertrophic Cardiomyopathy and psoriasis[4][5].
-
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.